ROXALL Medizin GmbH — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

1 Recruiting

8 Completed trials

2 Countries active

32 Unique IMPs

100% Results reported

Phase II/III

Phase II/III: 9

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

DERMATOPHAGOIDES PTERONYSSINUS EXTRACT 4 ALTERNARIA ALTERNATA EXTRACT 3 ARTEMISIA VULGARIS POLLEN EXTRACT 3 CAT EPITHELIUM EXTRACT 3 DOG EPITHELIUM EXTRACT 3 HISTAMINE DIHYDROCHLORIDE 3 LORATADINE 3 MOMETASONE FUROATE 3 SODIUM CHLORIDE 3 ALTERNARIA ALTERNATA (402) 2 AMBROSIA ARTEMISIIFOLIA (302) 2 ARTEMISIA VULGARIS (312) 2

All trials

9 total

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Pending

2024-517520-19-00 Phase II/III 1 country BETULA POLLEN EXTRACT
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy. A prosp… Recruiting

2025-523119-12-00 Phase II/III 2 countries DERMATOPHAGOIDES PTERONYSSINUS EXTRACT
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended

2024-517524-18-00 Phase II/III 1 country PHLEUM PRATENSE POLLEN EXTRACT
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy Ended

2024-517521-25-00 Phase II/III 1 country ALLERGEN EXTRACT FROM PHLEUM PRATENSE POLLEN, GLUTARALDEHYDE-MODIFIED
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy Ended

2024-517515-75-00 Phase II/III 1 country BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allerg… Ended

2024-517014-15-00 Phase II/III 2 countries DERMATOPHAGOIDES PTERONYSSINUS ALLERGOID, GLUTARALDEHYDE-MODIFIED
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen a… Ended

2024-511383-88-00 Phase II/III 1 country ALLERGENIC EXTRACT OF OLEA EUROPAEA POLLEN POLYMERIZED WITH GLUTARALDEHYDE; ALTE…
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended

2023-505880-35-00 Phase II/III 1 country ALTERNARIA ALTERNATA (402); ALTERNARIA ALTERNATA EXTRACT; AMBROSIA ARTEMISIIFOLI…
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended

2023-505567-37-00 Phase II/III 1 country ALTERNARIA ALTERNATA (402); ALTERNARIA ALTERNATA EXTRACT; AMBROSIA ARTEMISIIFOLI…

Showing 1–9 of 9 trials

← All sponsors A–Z